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Main Points: 
 Use of immunochemical methods without sufficient controls for specificity 
results in erroneous localization data. 
 We propose a strategy for protein localization and explain why quantitative 
considerations are important for specificity assessment. 
 
Keywords: Antibody specificity, Immunocytochemistry, Western blotting, Glutamate 
uptake, Excitatory amino acid transporter 
 
ABBREVIATIONS 
The abbreviations used are: BGT1; betaine-GABA transporter (slc6a12); DTT, 
dithiothreitol; EAAT1, glutamate aspartate transporter (GLAST; slc1a3); EAAT2, 
glutamate transporter 2 (GLT-1; slc1a2); EAAT3, excitatory amino acid carrier 
(EAAC1; slc1a1); EDTA, sodium ethylenediamine tetraacetate; GABA, gamma-
aminobutyric acid; GAT1, GABA transporter 1 (slc6a1); GAT2, GABA transporter 2 
(slc6a13); GAT3, GABA transporter 3 (slc6a11; mGAT4); KO, knockout; NaPi, 
sodium phosphate buffer with pH 7.4; SDS, sodium dodecyl sulfate; VGLUTs, 
vesicular glutamate transporters; WT, wild-type mice. 
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Abstract 
Immunocytochemistry and Western blotting are still major methods for protein 
localization, but they rely on the specificity of the antibodies. Validation of antibody 
specificity remains challenging mostly because ideal negative controls are often 
unavailable. Further, immunochemical labeling patterns are also influenced by a 
number of other factors such as post mortem changes, fixation procedures and 
blocking agents as well as the general assay conditions (e.g. buffers, temperature 
etc). Western blotting similarly depends on tissue collection and sample preparation 
as well as the electrophoretic separation, transfer to blotting membranes and the 
immunochemical probing of immobilized molecules. Publication of inaccurate 
information on protein distribution has downstream consequences for other 
researchers because the interpretation of physiological and pharmacological 
observations depends on information on where ion channels, receptors, enzymes or 
transporters are located. Despite numerous reports, some of which are strongly 
worded, erroneous localization data are being published. Here we describe the 
extent of the problem and illustrate the nature of the pitfalls with examples from 
studies of neurotransmitter transporters. We explain the importance of supplementing 
immunochemical observations with other measurements (e.g. mRNA levels and 
distribution, protein activity, mass spectrometry, electrophysiological recordings, etc) 
and why quantitative considerations are integral parts of the quality control. Further, 
we propose a practical strategy for researchers who plan to embark on a localization 
study. We also share our thoughts about guidelines for quality control. 
Page 3 of 80
John Wiley & Sons, Inc.
GLIA
  4 
Introduction 
An interest in utilizing antibodies as analytical tools began in the 1930s when 
investigators started to conjugate antibodies with other molecules. Albert H. Coons 
showed in the early 1940s that it was possible to use fluorescently tagged antibodies 
to localize antigens in tissue sections (Coons and Kaplan, 1950; Coons, 1971). Since 
then a multitude of different immunochemical methods have been developed. 
Western (protein) blotting was invented (Towbin et al., 1979) after the discovery that 
sodium dodecyl sulfate (SDS) could enhance the resolving power of electrophoresis 
gels (Laemmli, 1970). The methods became popular, but along with enthusiasm 
came concerns about the validity of the data generated (Petrusz et al., 1976; Petrusz 
et al., 1980; Petrusz, 1983). Some investigators even questioned if specificity could 
ever be proven (Swaab et al., 1977). Nevertheless, the techniques have been in 
widespread use for several decades for identifying individual proteins in complex 
biological samples (e.g. tissue extracts and sections), and have resulted in an 
enormous amount of new knowledge.  
 However, despite the understanding of the principles, the field of 
immunocytochemistry is still troubled by spurious results due to insufficient controls 
for specificity (e.g. Pool and Buijs, 1988; Griffiths, 1993; Brandtzaeg, 1998; Grube, 
2004;  Ramos-Vara and Miller, 2014; Holmseth et al., 2012a; Griffiths and Lucocq, 
2014).  
 In the present review, we try to explain the difficulties and still convey a 
positive message: how to do localization well. Although there are arguments in favor 
of detailed formal guidelines, it is hard to define the exact tests that should be 
performed (e.g. Saper and Sawchenko, 2003; Saper, 2005; Holmseth et al., 2006; 
Rhodes and Trimmer, 2006; Lorincz and Nusser, 2008; Fritschy, 2008; Saper, 2009; 
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Burry, 2011; Griffiths and Lucocq, 2014). After all, each project is unique and that 
uniqueness comprises both unique challenges and unique opportunities. Instead of 
formal rules we suggest a practical strategy which we illustrate with examples mostly 
from studies of neurotransmitter transporters in the brain (Zhou and Danbolt, 2013). 
This review has, however, broader implications as the localization of transporters is 
used to exemplify the trickier aspects of antigen-antibody interactions: the same 
rationale can be applied to almost any biomarker detection in cells and in tissues 
sections.  
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The extent of the problem is such that it should be taken seriously 
Several recent reports document poor specificity of commercially available 
antibodies. For instance, seven papers appeared in Naunyn-Schmiedebergs 
Archives of Pharmacology in 2009 highlighting a lack of selectivity of 49 antibodies 
against 19 subtypes of alpha(1)- and beta-adrenoceptors, muscarinic, dopamine and 
galanin receptors as well as vanilloid (TRPV1) receptors. These data demonstrate 
that lack of selectivity appears to be the rule rather than the exception for antibodies 
against G-protein-coupled and perhaps also other receptors (Michel et al., 2009; 
Kirkpatrick, 2009). Indeed, there are several reports of poor commercial antibodies to 
adrenergic receptors (Hamdani and van der Velden, 2009; Jensen et al., 2009) as 
well as to other proteins such as acetylcholine receptors (Herber et al., 2004; Moser 
et al., 2007), histones (Egelhofer et al., 2011), CD95 ligand (Strater et al., 2001), 
angiotensin receptors (Hafko et al., 2013; Herrera et al., 2013; Elliott et al., 2013), 
dopamine receptors (Bodei et al., 2009), cannabinoid receptors (Snyder et al., 2010; 
Ashton, 2012; Morozov et al., 2013), histamine receptors (Beermann et al., 2012), 
P2X receptors (Ashour et al., 2006) and others.   
 Together, these examples describe many poorly specific antibody products to 
about 100 different proteins. Researchers have been using precious research 
funding to buy these products, and subsequently waste even more resources when 
they use them to generate data. Fortunately, most of these data do not get published, 
but some do. And that may mislead other researchers to do less interesting 
investigations than they otherwise could have done. Even worse, some of these 
antibodies are used in medical diagnostics with potential consequences for patients.  
 One problem is poor testing when a product is first put on sale. Another is 
batch differences. Thus, when a researcher purchases a product with the same 
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product number, the properties of the antibodies may be significantly different. This 
has also been pointed out by multiple investigators (e.g. Strater et al., 2001; Bodei et 
al., 2009; Jensen et al., 2009; Herber et al., 2004; Grimsey et al., 2008; Kirkpatrick, 
2009; Herrera et al., 2013; Bohmer et al., 2014; Baker, 2015; Van Liefferinge et al., 
2016). 
 We therefore fully agree with those who argue that commercial antibody 
producers should test their antibodies more rigorously before selling them to 
scientists or pathologists who often lack the resources or expertise to evaluate 
acquired antibodies (Rhodes and Trimmer, 2006; Pradidarcheep et al., 2008; 
Couchman, 2009; Boenisch, 2006; Kalyuzhny, 2009; Bohmer et al., 2014; Baker, 
2015).  
 However, not all testing can be done in advance because the overall labeling 
specificity is affected by so many parameters that antibodies have to be tested for 
each application (e.g. Ottersen, 1987; Holmseth et al., 2006; Lorincz and Nusser, 
2008; Rhodes and Trimmer, 2006). Virtually all assay conditions can affect antibody 
binding, including protein conformation and hydrophobic interactions (e.g. pH, buffer 
composition, ionic strength), tissue handling steps (e.g. time to fixation, type of 
fixation, fixative composition, fixation time, storage after fixation) and antigen retrieval 
techniques.  
 So although the antibody producers do deserve criticism as explained above, 
neither the researchers themselves (Roth, 2006; Rhodes and Trimmer, 2006; 
Schonbrunn, 2014; Lorincz and Nusser, 2008) nor the editors of journals should 
avoid their responsibility (Smith, 2006). 
 Unfortunately, the problem is increasing due to highly sensitive imaging 
techniques, the ease by which images can be acquired and the pressure to publish. 
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Immunocytochemistry is a method that is able to produce publishable, but potentially 
incorrect data, at a high rate and low cost (Rhodes and Trimmer, 2006) This is a 
major concern considering the widespread use of these methods, the considerable 
effort required to correct inaccurate results and the downstream consequences for 
other researchers (e.g. Morrow and Friedrich, 2003; Roth, 2006; Rhodes and 
Trimmer, 2006; Steingart et al., 2007; Smith, 2006; Fritschy, 2008; Couchman, 2009; 
Kalyuzhny, 2009; Holmseth et al., 2012a; Herrera et al., 2013; Griffiths and Lucocq, 
2014). After all, the biomedical research community relies directly or indirectly on 
precise protein localization data because interpretation of the other methods (e.g. 
electrophysiological and pharmacological observations) depends on information on 
where ion channels, receptors, enzymes or transporters are located.  
[Figure 1 about here] 
 
Why it is difficult to verify labeling specificity 
A good antibody binds to the desired target with high affinity, allowing it to be used at 
concentrations well below the concentration where it starts to bind to other targets 
(see Fig. 1). The challenge, however, is that the number of possible antibody binding 
sites (epitopes) in a tissue section is virtually infinite, and their affinities for a given 
antibody are unknown. Consequently, it is hard to rule out the existence of unknown 
epitopes with high affinity for the antibody.  
 Obviously, antibodies are protein molecules which recognize the antigens 
much like receptor proteins recognize ligands or enzymes recognize substrates (Pool 
and Buijs, 1988; Griffiths, 1993; Holmseth et al., 2005). It should be recalled how 
medicinal chemists manage to develop new molecules that can compete with 
endogenous ligands despite very different chemical structures. From this perspective 
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it is not surprising that antibodies may cross-react with seemingly unrelated 
molecules. Since we made the first antibodies to a glutamate transporter (Danbolt et 
al., 1992), our laboratory has produced about one thousand different antibodies. 
Even after affinity purification, most still displayed some degree of cross-reactivity 
with unrelated molecules (Holmseth et al., 2012a). Thus, cross-reactivity is common 
(Davies et al., 2007) although the identities of the cross reacting molecular species 
are rarely determined.   
 Cross-reactivity does not have to imply that an antibody preparation is 
contaminated with unwanted antibodies derived from other B-cell clones. It can be 
due to the same antibodies as those recognizing the antigen under study (Danbolt et 
al., 1998; Holmseth et al., 2005; Wilson et al., 1996). Consequently, even monoclonal 
antibodies can display cross-reactivity. In fact, when we made monoclonal antibodies 
to EAAT2 (Levy et al., 1993) we also isolated clones producing polyreactive 
antibodies (Danbolt et al., 1998). The cross-reactivity is often unexpected. For 
instance, antibodies to a glutamate transporter (Holmseth et al., 2005) and carbonic 
anhydrase (Li et al., 2009) cross-reacted with tubulin. Similarly, anti-DNA antibodies 
recognized peptide sequences (Sibille et al., 1997; James et al., 1999), dextran 
sulfate (Kinoshita et al., 1989) and even the NR2 glutamate receptor (DeGiorgio et 
al., 2001). Mitochondria represent a frequent site of cross-reactivity (e.g. Holmseth et 
al., 2006; Yang et al., 2006; Morozov et al., 2013). Reactivity with unrelated epitopes 
is elegantly illustrated when phage display is used to test antibodies (Sibille et al., 
1997; Menendez and Scott, 2005).  
 It should also be realized that tissue processing and fixation chemically 
modifies the tissue (Rasmussen and Albrechtsen, 1974; Somogyi and Takagi, 1982; 
Berod et al., 1981; Leong and Gilham, 1989; Korogod et al., 2015), leading to the 
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creation and elimination of epitopes. For instance, a monoclonal antibody to vimentin 
reacted with enamel proteins, but only after glutaraldehyde fixation (e.g. Josephsen 
et al., 1999; Willingham, 1999). Fixation of immunoblots prior to immunolabeling is a 
simple inexpensive way to get some assessment of the effect of this manipulation 
(Holmseth et al., 2006; Holmseth et al., 2012a). 
 
Reporter mice as an independent verification 
A large number of genetically modified mouse lines (Table 1) are now available to the 
public (e.g. Heintz, 2001; Nagy and Mar, 2001; Mori et al., 2006; Pfrieger and Slezak, 
2012). The genetic modifications not only comprise deletion of genes (knockout 
mice), but also insertion of DNA that was not there originally. The inserted DNA can 
for instance be encoding enzymes or fluorescent proteins (e.g. Livet et al., 2007). 
Reporter mice, where promotor activation results in expression of fluorescent 
proteins, can be used as an alternative, or as a supplement, to immunocytochemistry 
(Nolte et al., 2001). This offers new opportunities for studies of cell progeny (e.g. 
Malatesta et al., 2003; Zhu et al., 2008; Platel et al., 2009; Huang et al., 2014), 
visualization of astrocytes and astrogliosis in living brain tissue (Nolte et al., 2001; 
Weimer et al., 2008; Tang et al., 2009) and other dynamic interactions which are hard 
to study immunocytochemically (e.g. Reichenbach et al., 2010; Young et al., 2010; 
Herzog et al., 2011). There are, however, issues with reporter mice also as the 
transcriptional activity can be influenced by multiple factors. Therefore the expression 
patterns can be altered depending on how promotor elements are affected (Yeo et 
al., 2013). Nevertheless, the distribution of fluorescence in reporter lines for the 
EAAT1, EAAT2 and EAAT4 glutamate transporters (Regan et al., 2007; Gincel et al., 
2007; de Vivo et al., 2010a; de Vivo et al., 2010b) is in good agreement with previous 
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immunocytochemistry (Lehre et al., 1995; Dehnes et al., 1998; Zhou and Danbolt, 
2014). A review of the potential of genetically modified animals, however, is beyond 
the scope of this review.  
 
The expression levels required for physiologically significant function 
How much protein is necessary to account for the proposed or measured function? 
This question becomes more important as increasingly sensitive detection techniques 
are developed. In this context, it is worth noting that most DNA is transcribed (Birney 
et al., 2007). Although it is not known if all mRNA is translated, it should be asked 
whether the detected molecules have the capacity to accomplish the proposed or 
measured tasks at physiologically relevant rates. The number of molecules needed to 
accomplish a given task depends on what that task is. Some proteins (e.g. primary 
activators of a cascade system such as the complement system) can deliver 
significant effects when present in minute quantities, while other proteins may only 
make a difference if highly expressed.  
 Neurotransmitter transporters are examples of proteins that need to be 
present in high numbers because co-transport is a relatively slow process requiring 
tens of milliseconds for completion of a single transport cycle (e.g. Grewer and 
Rauen, 2005; Karakossian et al., 2005; Gonzales et al., 2007; Gameiro et al., 2011; 
Zhou et al., 2014a; Hanson et al., 2015). Thus, one transporter molecule can only 
transport a couple of dozen substrate molecules per second at Vmax. Sub-
millisecond transmitter removal requires more vacant binding sites (transporter 
molecules) than released neurotransmitter molecules. This is because low molecular 
mass compounds, such as amino acid neurotransmitters, diffuse quickly out of the 
synaptic cleft on a low microsecond timescale until they bind to transporters and are 
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removed (e.g. Clements, 1996; Tzingounis and Wadiche, 2007). Another reason why 
high numbers of transporters are required follows from the low resting levels of 
extracellular GABA (e.g. Westergren et al., 1994) and glutamate (Herman and Jahr, 
2007) despite rapid neurotransmitter release (e.g. Jabaudon et al., 1999). 
Maintenance of resting levels far below the Km-values of the transporters (Danbolt, 
2001; Conti et al., 2004) requires a vast excess of transporters (Bergles and Jahr, 
1997; Otis and Kavanaugh, 2000; Herman and Jahr, 2007) in agreement with 
biochemical measurements of transporter concentrations (Lehre and Danbolt, 1998; 
Holmseth et al., 2012b).  
 In contrast to fast transmitter removal, less demanding needs that can be 
satisfied in minutes or hours rather than milliseconds may require fewer transporters. 
Thus, if a physiological role can be demonstrated and the numbers of protein 
molecules are insufficient, then it should be asked whether the protein can mediate 
its effect via novel mechanisms that require fewer molecules e.g. by acting as a 
receptor or ion channel. For instance, tens of thousands of ions may pass through an 
ion channel per second implying that relatively few channels can mediate significant 
ion fluxes. In fact, the EAAT4 (slc1a6) and the EAAT5 (slc1a7) glutamate 
transporters may function as glutamate gated anion channels (Dehnes et al., 1998; 
Veruki et al., 2006; Gameiro et al., 2011; Schneider et al., 2014). 
 Another parameter to consider is if the cells supposed to be expressing a 
given transporter can make use of it, e.g. do they have enough energy to operate all 
of the transporters, and is their plasma membrane surface area large enough to 
accommodate all of the transporter molecules? This argument is particularly relevant 
when reporting expression of transporter proteins in endothelial cells which are flat 
with few mitochondria and fairly smooth plasma membranes. The opposite are cells 
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like those found in the proximal tubules in the kidneys that are packed with 
mitochondria and have huge surface areas due to abundant microvilli. Consequently, 
a large number of transporter molecules can fit into their plasma membranes, and the 
cells have energy to fuel them.  
 
Suggested strategy when embarking on a localization project 
1. Does the tissue of interest perform functions attributable to the protein to be 
localized?  
Before embarking on a project, it is a good idea to verify that the tissues of interest 
actually express the antigen to be studied at levels that may be functionally relevant. 
Can protein function be measured (e.g. transport activity or enzymatic activity)? Will 
these protein levels be detectable? Are other proteins with similar function expressed 
in the same tissue at higher concentrations? Glutamine transporters illustrate this 
point as there are at least 14 of them (Bhutia and Ganapathy, 2015). It may be 
worthwhile to search available microarray, transcriptome and proteome datasets (e.g. 
Lu et al., 2009; Walther and Mann, 2011; Ulrich et al., 2014; Holtman et al., 2015) as 
these may give good indications of which proteins it may be possible to detect. 
 
2. Sample quality - proteolysis and true oligomers versus in vitro aggregation 
Since the tissue samples to be studied represent the material on which the entire 
study is founded, both the quality and the processing of the samples are key factors.  
 Several general descriptions are available on how to preserve protein stability 
(e.g. Deutscher, 1990), how to purify (e.g. Linn, 1990), how to isolate membranes 
and make extracts (e.g. Dignam, 1990; Ozols, 1990) and how to solubilize (e.g. 
Neugebauer, 1990; Hjelmeland, 1990). In fact, multitudinous methods have been 
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developed for different purposes, but this is beyond the scope of this review. Here we 
only want to point out two factors that have caused some confusion within studies of 
glutamate transporters, namely (a) post-mortem proteolysis and (b) differences 
between true oligomers and cross-linking resulting from sample preparation.  
 (a) Post-mortem artifacts (Figs. 2 and 3): Tissue from autopsies has proven 
invaluable in studies of diseases, including neurological diseases, but the post-
mortem interval (time from death to tissue preservation) can influence the results of 
the investigations. Changes are readily detected by proteomic analyses after 6 hours 
(Machaalani et al., 2010). If all proteins had been degraded at the same rate in all 
cells, then the post-mortem interval would only have affected the sensitivity. 
However, this is not the case. The rates of degradation vary greatly between different 
proteins and between brain regions (Patel et al., 1993; Martin et al., 2003; Wang et 
al., 2000; Li et al., 2012; Rutkiewicz and Basu, 2012). This might in fact be expected 
considering that the distributions of proteins (enzymes included) are not uniform, and 
that many of the post-mortem alterations result from dynamic processes (Geddes et 
al., 1995; Goni-Oliver et al., 2009; Yeh et al., 2009; Li et al., 2012). For instance, the 
N- and C-termini of EAAT2 glutamate transporter (GLT-1; slc1a2) degrade faster 
than those of its close relative, EAAT1 (GLAST; slc1a3) which in turn degrade faster 
than the C-terminus of EAAT3 (EAAC1; slc1a1). In contrast, epitopes within central 
parts of the EAAT2 protein, e.g. residues 107-120 and 493-508 (Beckstrøm et al., 
1999; Li et al., 2012) as well as to residues 146-161 (Fig. 2) are far more resistant. 
Similarly, the NR2A and NR2B glutamate receptor subunits are proteolyzed faster 
than the other NMDA and AMPA types of glutamate receptors (Wang et al., 2000). 
Further, EAAT2 is proteolyzed faster in the cerebral cortex than in the striatum (Li et 
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al., 2012).Thus, the labeling pattern obtained depends both on the post mortem 
interval and the antibodies used (Tessler et al., 1999; Li et al., 2012).  
[Figure 2 about here] 
[Figure 3 about here] 
 (b) True oligomers vs artifactual cross-linking: Another factor that has been 
confusing to researchers studying glutamate transporters is preservation of in vivo 
oligomeric structure versus in vitro cross-linking or aggregation (Figs. 4 and 5). The 
EAAT2 glutamate transporter exists in the brain as homo-trimers where the subunits 
are non-covalently attached to each other (Haugeto et al., 1996; Yernool et al., 2004; 
Gendreau et al., 2004). When fresh brain tissue is rapidly homogenized directly in 
sodium dodecyl sulfate (SDS), only monomers are seen on the Western blots 
regardless of whether reducing agents have been added (Fig. 4, Lane 1). The native 
oligomers can be visualized if they are preserved by chemical cross-linking prior to 
solubilization of the membranes in which they reside (see Fig. 5A).  
 If the intact brain membranes are oxidized (Fig. 4, Lane 2), then covalent 
bonds form between one EAAT2 subunit and other molecules (Trotti et al., 1998; 
Danbolt, 2001). Whether this is another EAAT2 subunit, or something else, is not 
known at the moment. These complexes, however, are not seen if the samples are 
subjected to reducing agents or if oxidation occurs after solubilization in SDS. 
[Figure 4 about here] 
The phenomenon that causes confusion is therefore a different one: the solubilization 
procedure affects the electrophoretic mobility pattern of EAAT2. If the tissue is 
solubilized with mild detergents (e.g. cholate or Triton X-100) and not in SDS, then 
complexes form even under reducing conditions (Fig. 5B). Once formed, these 
complexes are resistant to SDS. The formation is enhanced at elevated temperatures 
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(Fig. 5B) and prevented by addition of phospholipids (not shown). To what extent this 
reflects irreversible attachment of subunits in endogenous oligomeric complexes or 
later aggregation in vitro depends on the in vitro conditions (e.g. protein and salt 
concentrations). Thus, it is important to realize that variations in sample handling 
have major effects and that it should not be taken for granted that changes in the 
proportions between monomers and oligomers observed on Western blots reflect real 
differences in oligomeric structure in vivo. Unfortunately, this assumption is now 
commonly found in the literature. For instance, a number of investigators have used 
the so called "RIPA Lysis and Extraction Buffer" which contains SDS in combination 
with deoxycholate and sometimes a non-ionic detergent. When brain tissue is 
solubilized in this buffer, oligomeric bands are seen. This buffer is not suitable for 
quantitative examination of glutamate transporters. 
[Figure 5 about here] 
A related point that merits emphasis is the difficulty in quantifying proteins on 
Western blots when the proteins are distributed between monomers and dimers or 
higher order aggregates. The reason is that the labeling intensity measured depends 
on several factors such as the efficiency of solubilization of the protein under study, 
the entry into the electrophoresis gel, the percentage that leaves the gel during 
electrophoretic transfer, the percentage that is captured on the blotting membrane 
and the availability of the epitopes for antibody binding. One or more of these 
parameters are likely to differ between monomers and multimers.     
 
3. Acquisition of antibodies 
When obtaining antibodies from others, it is important to make sure that all relevant 
documentation is available. We fully agree that data obtained with insufficiently 
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documented antibodies, should not be published (e.g. Saper and Sawchenko, 2003; 
Saper, 2005; Rhodes and Trimmer, 2006; Fritschy, 2008; Holmseth et al., 2012a). 
Both the source of the antibody and the exact antigen used for immunization should 
be known to the investigators, at least for main antibodies that a study relies on. If the 
antiserum was purified in some way, then this should also be recorded. As explained 
above, there may be significant differences between antibody batches so it is 
important to refer to the exact batch (e.g. batch number, production date). When 
monoclonal antibodies are produced in the form of ascites fluid, then they will be 
contaminated with other antibodies from the host mouse. These contaminating 
antibodies may vary from batch to batch. The batch number should therefore be 
recorded also when monoclonal antibodies are used. 
  Obviously, it is an advantage if several different antibodies to the same target 
can be obtained. Then it can be seen whether they all give the same results.  
 If the plan is to do extensive studies of a particular protein, it is worthwhile to 
make the antibodies rather than buying them. That is costly, but if large amounts are 
needed, then it may still be cheaper and safer than purchasing and testing several 
small aliquots from different batches from commercial suppliers. Antibody production 
is straight forward. We typically immunize with synthetic peptides and prefer a 
"shotgun-approach": we select the hydrophilic portions of the termini (the longer the 
better) as well as other parts of the protein, mix the peptides together with carrier 
protein and glutaraldehyde, and inject this subcutaneously (for details see: Danbolt et 
al., 1998; Holmseth et al., 2005). We avoid intracutaneous injections as they cause 
unnecessary suffering.  
 
4. What is the evidence that the antibody recognizes the antigen? 
Page 17 of 80
John Wiley & Sons, Inc.
GLIA
  18
Unfortunately, it cannot even be taken for granted that an antibody binds to the 
antigen at all. Therefore, one of the first things to do is to obtain a positive control: a 
sample that contains the native antigen of interest in high concentrations. For 
instance, mature forebrain tissue is a very good source of EAAT1, EAAT2, GAT1 and 
GAT3 (Lehre et al., 1995; Ribak et al., 1996; Conti et al., 2004; Melone et al., 2015), 
while cerebellum and kidney are, respectively, good sources of EAAT4 (Dehnes et 
al., 1998) and EAAT3 (Holmseth et al., 2012b). Transfected cell cultures may be 
chosen for proteins of unknown distribution or for proteins only expressed at low 
levels.  
 It is important that the antigen used as a positive control resembles the natural 
one as much as possible. For instance, immunization with peptides usually gives 
antibodies that recognize the peptides, but many of these antibodies (the majority in 
fact) do not recognize the intact protein for various reasons (see: Danbolt et al., 
1998). The choice of method for testing depends on how the antibodies have been 
made. Immunoblotting is excellent for most antibodies to synthetic peptides or 
purified proteins, but is not optimal in cases where the antibodies have been 
produced and selected for their ability to recognize protein complexes or specific 
conformations. However, conformation specific antibodies are exceptions so positive 
proof is required before arguments that antibodies work for immunocytochemistry 
and not for immunoblotting can be accepted. It is also worth checking that the 
antibodies recognize the antigen after the same treatment as the tissue will be 
subjected to (fixation, embedding, antigen retrieval etc: Josephsen et al., 1999; 
Holmseth et al., 2006; Holmseth et al., 2012a). This will also give a first indication of 
the sensitivity that can be obtained.  
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5. Specificity testing by immunoblotting 
As stated above, most antibodies should be tested by immunoblotting. It is important 
to make extracts from the tissues in which the distribution of the antigen is going to 
be studied because the gene expression profiles vary greatly between cell types. It is 
essential to test the antibodies on blots containing as many tissue antigens as 
possible, so whole tissue homogenates should be used. However, non-transporter 
molecules present in the samples may block binding of the transporters to the 
membranes (Fig. 6). This was noted a long time ago (Danbolt et al., 1992) and can, 
at least partly, be avoided by homogenizing the tissue in water and centrifuging to 
separate water soluble and water insoluble proteins. In fact, when we made 
antibodies to the betaine-GABA transporter (BGT1; slc6a12) we initially thought that 
the antibodies did not work and we made new antibodies. About ten years later, we 
homogenized the transfected cells in water to remove the water soluble proteins. 
Then we realized that many of the antibodies were excellent, but that BGT1 had not 
been immobilized on the blotting membranes due to interference from non-BGT1 
proteins (Zhou et al., 2012a).  
[Figure 6 about here] 
Separation of water soluble and water insoluble proteins can be used to test 
specificity. Because transporter proteins are integral membrane proteins, they are 
supposed to be found in the membrane fraction. If the immunoreactivity is in the 
water soluble fraction, this is a warning that the antibodies bind to something other 
than an integral membrane protein. Extracts from mouse pancreas illustrate this (Fig. 
7). EAAT2 antibodies cross-react with a water soluble protein with a molecular mass 
that is similar to that of EAAT2. This cross-reactive protein is present in both wildtype 
mice and EAAT2 knockout mice. EAAT2 protein itself is not detectable in young adult 
Page 19 of 80
John Wiley & Sons, Inc.
GLIA
  20
mouse pancreas (Zhou et al., 2014b). The identity of the cross-reacting antigens is 
unknown, but it is interesting that islet cells contain several proteins that often give 
rise to autoantibodies (Arvan et al., 2012). Some of these proteins have molecular 
masses similar to that of EAAT2, and such antibodies may be present in rabbit sera. 
 Contaminating cross-reactive antibodies often require active removal by 
absorption. This is illustrated with antibodies to a peptide representing residues 479-
492 of rat EAAT3 (Bjørås et al., 1996). This peptide gave rise to antibodies with high 
affinity to both tubulin and EAAT3 (Holmseth et al., 2005). The antisera had first to be 
passed through a column with immobilized tubulin to remove antibodies reacting with 
tubulin. Then the remaining antibodies with affinity to EAAT3 could be isolated.  
[Figure 7 about here] 
In our experience, immunoblots are informative: antibodies that look specific on blots 
are often specific in sections. Nevertheless, exceptions are common so immunoblots 
should be supplemented with other tests whenever possible (Holmseth et al., 2005; 
Holmseth et al., 2012a). Further, cross-reactivity can be highly specific and localized 
(Josephsen et al., 1999; Holmseth et al., 2012a). It is not surprising that antibodies 
may display different degrees of specificity when tested on immunoblots and on 
sections considering that the former is based on molecules that have been 
solubilized. The molecules may have different conformations and are likely to be 
separated from their natural molecular neighbors during electrophoresis. Further, the 
smallest and the largest molecules are lost, and the three dimensional structure of 
the tissue is destroyed. In contrast, the three dimensional structure is preserved in 
sections, but the tissue is often chemically modified and some components may be 
lost depending on the tissue processing used. It is also important to remember that 
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one band on an immunoblot may contain more than one protein (Holmseth et al., 
2012a).  
 
6. Testing on tissue sections 
If a signal cannot be obtained on tissue sections, then the technique has to be 
modified. However, as illustrated (Fig. 1), a signal can usually be obtained by 
adjusting fixation conditions, blocking conditions, salt concentrations, pH and 
antibody concentrations or by employing antigen retrieval techniques (e.g. Shi et al., 
2011) and methods for labeling enhancement such as gold-silver intensification (e.g. 
Dobo et al., 2011) and tyramide signal amplification (Kerstens et al., 1995; 
Silahtaroglu et al., 2007). It is therefore necessary to ask critical questions such as: 
does this labeling only represent the antigen of interest or is it due to something else 
instead of, or in addition to, the antigen of interest? Immunolabeling does not in itself 
prove that the protein is present. Beware of sampling error: "Finally I found an 
antibody that worked!" What is the definition of a good antibody? Unfortunately, quite 
often a good antibody is one that gives the expected or desired labeling. This brings 
up another factor, namely quality control by an experienced scientist and proper 
training of new recruits. Thus, sampling errors like this may occur if the 
communication between a junior team member and the principal investigator is 
insufficient.  
 If the labeling represents the right antigen, then the tissue distribution in 
sections should match the labeling of the corresponding bands on immunoblots. A 
simple test is to dissect regions with different labeling intensities and then check if the 
labeling intensities obtained on immunoblots match those seen in tissue sections. 
Discrepancies should raise concerns about antibody specificity. However, differences 
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in tissue water content may affect fixation and thereby antibody penetration into the 
tissue (see discussion about the use of detergents in: Danbolt et al., 1998; Heffer-
Lauc et al., 2007). Also as explained above, (Fig. 5), non-transporter proteins may 
interfere with the binding of transporters to the blotting membranes causing 
underestimation of expression levels.  
 The strength of these tests will be greater if several antibodies give the same 
result. However, variable splicing can be a reason they may not. And if they give the 
same result, then it is still possible that they all have the same cross-reactivity as 
illustrated above with pancreas (Fig. 6) and shown by others (Davies et al., 2007). 
Further, if the antibody concentration needed for obtaining labeling of sections is 
considerably higher than that needed to label Western blots, then this may be due to 
the fundamental differences between blots and sections (see above). Alternatively, it 
might be a sign that the data do not quite fit with the working hypothesis. 
 
7. Testing on genetically modified tissue 
If the antibodies look promising, it is worthwhile to find out if suitable genetically 
modified organisms exist. Knockout animals are animals where a gene has been 
deleted and represent very powerful negative controls (e.g. Herber et al., 2004; 
Holmseth et al., 2005; Holmseth et al., 2012a; Li et al., 2013; Cecyre et al., 2014; 
Van Liefferinge et al., 2016; Baek et al., 2013; Bohmer et al., 2014). The main 
problem is their availability and the fact that most are mice while most 
immunocytochemistry is done on rat and human tissue. However, with human 
samples in particular, there may not be any good negative controls at all. So despite 
obvious limitations, tissue from knockout mice may still be the best negative control 
available. Fortunately, a huge number of animals with various modifications of their 
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genomes are now available and the list is rapidly becoming longer (e.g. Nagy and 
Mar, 2001; Skarnes et al., 2011; Table 1). For instance, knockout mice for most of 
the glutamate and GABA transporter genes are available: EAAT1 (Watase et al., 
1998), EAAT2 (Tanaka et al., 1997; Zhou et al., 2014b), EAAT3 (Peghini et al., 
1997), EAAT4 (Huang et al., 2004), glutamate-cystine exchanger (xCT; slc7a11; Sato 
et al., 2005), GAT1 (Chiu et al., 2005), GAT2 (Zhou et al., 2012b) and BGT1 (Lehre 
et al., 2011; Zhou et al., 2012a). In conventional (global) knockout animals the target 
gene is absent already before conception and is therefore absent in all cells during 
development. One advantage for use as negative controls in immunocytochemistry 
experiments is that all cells lack the gene. On the other hand no mice will be born if 
the deletion is lethal early in development. Although compensatory changes or 
downstream consequences of the deletion may complicate interpretation, such 
animals have nevertheless been extremely useful. 
 The EAAT2 knockout mice (Tanaka et al., 1997) illustrate several points. They 
are inconspicuous at birth because EAAT2 is hardly expressed (Ullensvang et al., 
1997), but become hyperactive and develop epilepsy after three weeks. About half of 
them die suddenly before the end of the fourth week. This agrees with biochemical 
studies showing that EAAT2 is the major glutamate transporter in adult brain (Danbolt 
et al., 1992; Otis and Kavanaugh, 2000).  
 Another limitation of knockout animals can be other genes containing the 
same sequence, or residual expression of the deleted gene. It is common to select a 
few critical exons that are necessary for function. Although this eliminates the 
function, a truncated protein may still be expressed unless the DNA is deleted in such 
a way that a frame-shift is introduced resulting in both a stop codon and a 
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meaningless protein sequence. Unfortunately, not all knockouts have been 
constructed with this in mind.  
 Further, when a gene is deleted, this may affect expression of other genes 
(Teng et al., 2013; Ghule et al., 2015). Cross-reactive molecules may be down-
regulated or up-regulated. However, if an antibody gives rise to labeling in knockout 
tissue, then this should not be taken lightly. Unless proven otherwise, labeling of 
samples from knockout animals should be considered cross-reactivity. Obviously, this 
argument is only valid if the protein is truly absent in the knockout animals as 
explained above. 
 It is also important that the conditions used during specificity testing have to 
match the conditions during data acquisition (e.g: Lorincz and Nusser, 2008; Rhodes 
and Trimmer, 2006). The optimal solution is to process tissue from wild-type and 
knockout littermates together. This may not always be possible, but the testing 
should at least be done with the same method. Further antibody specificity tests 
should be conducted in the specific tissue to be examined, as the cross-reactivity can 
be regional or tissue-specific (Everaerts et al., 2009; Holmseth et al., 2012a; Ashour 
et al., 2006).  
 
Comment on the pre-adsorption control 
Antigen pre-adsorption was originally introduced to validate antisera containing 
mixtures of antibodies with a large variety of specificities (e.g. Pool and Buijs, 1988). 
This test tells if the labeling is due to the same antibodies as those recognizing the 
antigen. Importantly, it does not tell if the observed labeling represents a specific 
visualization of the antigen under study or if it is due to cross-reaction with other 
molecules (e.g. Swaab et al., 1977; Pool and Buijs, 1988; Burry, 2000). Despite this, 
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pre-adsorption is still regarded by many as an obligate control for the verification of 
immunocytochemical labeling - even labeling obtained with monoclonal and affinity 
purified antibodies. This is unfortunate as the pre-adsorption test can give a 
misleading impression of specificity (for illustrations see: Holmseth et al., 2012a). 
Compounding this problem, it is often costly to obtain enough free antigen to perform 
the test, diverting time and resources from more definitive experiments. 
 
Correlation between labeling intensity in tissue sections and protein levels   
As noted above, quantitative considerations are important, not only to understand 
function, but also to judge specificity. Are the expression levels high enough to be 
detectable? If not, then the labeling may be artifactual. 
 The high expression levels of glutamate transporters (Lehre and Danbolt, 
1998) are part of the reason why the first post-embedding immunogold electron 
micrographs of EAAT1, EAAT2 and EAAT4 (Chaudhry et al., 1995; Dehnes et al., 
1998) were so successful: there were sufficient numbers of EAAT molecules in the 
plane of the section to give convincing labeling. This also explains, at least partly, 
why we initially failed to detect EAAT2 in axon-terminals. Despite early reports 
suggesting glutamate uptake by nerve terminals, it took a long time to realize that this 
was due to EAAT2 (Danbolt et al., 2016).   
 The reasons why post-embedding immunogold electron microscopy (van den 
Pol, 1989; Ottersen, 1989) has relatively low sensitivity is that only the proteins that 
are in the exact sectioning plane are detected (for method see: Danbolt et al., 1998; 
Amiry-Moghaddam and Ottersen, 2013). The tissue sections used for electron 
microscopy are thin (45-90 nm) and not much thicker than the outer diameter of 
synaptic vesicles (40 nm), and only a few times thicker than the width of the neuronal 
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synaptic cleft (usually 20 nm). Further, despite the thinness, the antibodies do not 
penetrate well into the sections because of the resins in which the tissue is 
embedded. To maximize labeling intensity, sections are often labeled on both sides. 
Thus, the antibodies label only the molecules exposed at the surface. Chemical 
modification (fixation etc) can reduce the availability of epitopes even more. A high 
density of gold particles along a cut membrane is therefore only expected if the 
expression levels are very high. The sensitivity of post-embedding is thus low 
compared to e.g. fluorescent based labeling of free-floating sections. Consequently, if 
labeling is seen with immuno-gold and not with fluorescence based microscopy, then 
there is a mismatch which probably warrants extra control experiments.  
 Another challenge follows from the vulnerability of the ultrathin sections and 
thereby also the labeling. These sections are easily damaged during processing. 
Parts of the sections may be missing and the labeling uneven on the remaining parts.   
Consequently, there is variability and this leads to another challenge: enforcing strict 
quality controls in image acquisition to avoid sampling error. This challenge comes in 
addition to those mentioned above (specificity, proteolysis etc) and represents 
another example of a situation where results may depend on experience. Students 
may be inspired by an exciting hypothesis and go to the microscope to photograph 
unconsciously what the principal investigator hypothesized. A number of images are 
acquired and subjected to statistical analyses. The principal investigator may not 
realize that image collection is already biased. 
 To understand brain tissue, it is important to relate to the sizes of the cellular 
extensions. The following calculation may serve as an illustration: There is about one 
synapse per cubic micrometer brain tissue (gray matter; for references see: Danbolt, 
2001), and there are 1015 cubic micrometers in one liter. If this number is divided by 
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Avogadros number, it follows that the concentration of synapses is in the equivalent 
of approximately 1 nanomol/liter. The purpose of this rather unorthodox way of 
expressing synapse density is to illustrate that a protein has to be highly expressed if 
it is present in several copies per glutamatergic synapse (which represents the 
majority of brain synapses).  
 The sizes of the tiny cellular extensions making up brain tissue (the neuropil 
part of it) may be easier to grasp if they are compared to a red blood cell 
(erythrocyte). A human erythrocyte is about 7 µm in diameter. This means that the 
diameter of a red blood cell is about 9 times larger than the scale bar shown in figure 
8. A plasma membrane is about 5 nm thick and the width of the extracellular space 
(the distances between neighboring cellular extensions) is typically in the range 20-
40 nm, while the diameter of a glutamate transporter trimer is believed to be about 8 
nm (Yernool et al., 2004). Cellular elements are tightly intermingled (Kirov et al., 
1999; Sorra and Harris, 2000; Witcher et al., 2010; Harris and Weinberg, 2012; 
Mathiisen et al., 2010). This is schematically illustrated in figure 8. This means that 
the total amount of plasma membrane is large: about 14 µm2/µm3 in the stratum 
radiatum, rat hippocampus CA1 (Lehre and Danbolt, 1998). 
[Figure 8 about here] 
 The closeness of neuronal and glial membranes also adds problems with 
tissue localization, even at the resolution of electron microscopy. In attempting to 
reconcile data suggesting that EAAT2 was present in both neurons and astrocytes, 
we went to some lengths before we could be sure of the distribution of this 
transporter. Localization to astrocytes was clearly evident from the distribution of 
immungold label over astrocyte membrane/profiles; but how could a low level of 
expression of EAAT2 be ruled in or out, since the membranes are close together 
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(Fig. 9)? Although much higher resolutions can be achieved by electron microscopy 
than by light or confocal microscopy, even for electron microscopy the lateral 
resolution of immunogold labeling (~28 nm with 15 nm gold particles, Matsubara et 
al., 1996) means labeling on membranes within 40 – 50 nm or each other is 
ambiguous. One way around this was by embedding a suspension of synaptosomes 
where nerve terminals could be distinguished completely from glial membranes. A 
low level of expression in the nerve terminal membrane was then observed (Fig 9) 
(Furness et al., 2008)). 
[Figure 9 about here] 
[Figure 10 about here] 
 
Beware - convincing images are seductive 
If the hypothesis is intriguing and the images appear to match it closely, it is easy to 
be carried away and accept the appearance at first sight (Roth, 2006). For instance, 
during the work to localize the EAAT3 glutamate transporter subtype (Holmseth et al., 
2012b) we wanted to test if we could reproduce the perisynaptic distribution observed 
by others (He et al., 2001). To do this, post-embedding immuno-gold labeling was 
performed (Furness et al., 2008). Very convincing images were obtained (Fig. 11). 
Afterwards (but before publication) we obtained EAAT3 knockout mice (Peghini et al., 
1997) and used them as negative controls. The same labeling pattern was seen. This 
was very disappointing and our reaction was accordingly: "This cannot not be true! It 
must be something wrong with the knockout mouse!" However, after more hard work 
testing the knockout mouse, we had to accept that we could not find anything wrong 
with it. The consequence was that the labeling pattern observed was an artifact. We 
had to scrap the data. This was a double knockout, indeed.  
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[Figure 11 about here]  
 
Some thoughts about guidelines for immunocytochemistry 
Since the field of immunocytochemistry is, as outlined above, still troubled by 
spurious results due to insufficient controls of antibody specificity, the arguments for 
improvements in quality control are strong. It is, however, hard to define the exact 
tests that should be performed. Although there are arguments for formal rules, we 
fear that such rules may cause problems. To improve quality and help advancing 
science, formal rules will have to be exact and very complex. Worse, they will be 
based on present knowledge. Because each project has unique challenges, but also 
opportunities, freedom is important. Skilled investigators will come up with smart 
solutions exploiting the opportunities and trying to circumvent the obstacles. Further, 
the demand for rigorous testing depends on the type and focus of each study. The 
testing has to be more rigorous if immunocytochemistry is the main focus than if it is 
a side issue. Similarly, testing can be less stringent if the data are confirmatory. On 
the other hand if the authors report that previous investigators have overlooked 
something, then the question is whether this is really the case or whether the 
antibodies in the new study cross-react with other molecules. Further, the technical 
difficulties involved need to be considered. It is for instance more difficult to localize 
proteins expressed at low levels than highly expressed proteins. Although highly 
sensitive techniques are available (e.g. tyramide signal amplification: Kerstens et al., 
1995; Silahtaroglu et al., 2007), the specificity becomes more challenging as it 
becomes more likely that a cross-reacting molecular species might contribute more to 
the overall labeling than those under study. 
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 To give room for novel approaches, perhaps it would be sufficient to ask the 
authors to explain in detail why they believe their labeling is specific. If the authors 
are pushed to explain the logic behind their conclusions, a judgment can be made 
whether this is good enough for the present purpose and situation. Because it is 
logically impossible to prove absolute specificity, some uncertainty must be 
acceptable. The degree of permissible uncertainty must be judged in each case. 
Testing is expensive and time-consuming. The following points may be addressed: 
# What is the evidence that the antibody recognizes the target antigen, and still does 
so after the treatment that the tissue has been subjected to? 
# Why is it likely that the labeling represents the antigen of interest and nothing else? 
# Does the tissue express the target antigen at detectable levels? Is the labeling 
intensity in reasonable agreement with expression levels? Multiple factors can affect 
the labeling intensity so definite conclusions can only be made if the antibody has 
been calibrated against known protein concentrations under identical conditions. 
However, strong labeling of sections despite low mRNA levels and weak or absent 
signal on Western blots are examples of mismatches that warrant extra specificity 
controls.  
# Does the labeling pattern in sections correlate with data from other methods, e.g. 
Western blots and in situ hybridization? For instance, if the labeling seen in sections 
is stronger in the hippocampus than in the cerebellum, then a similar difference is 
expected on immunoblots. Another example, if intact cells display very little, but still 
detectable glutamate uptake activity, then one or more glutamate transporting 
proteins must be present in their plasma membranes. If in this situation antibodies to 
relevant transporters fail to detect labeling in the plasma membranes, but give rise to 
strong labeling of mitochondria, then the most likely interpretation is that the 
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mitochondrial labeling is due to cross-reactivity and the absence of plasma 
membrane labeling is due to expression levels below the detection limit.  
# Can the tissue or subcellular localization be confused? Can specific structures be 
adequately isolated from each other microscopically to be certain where the labeling 
is distributed? 
# Quantitative considerations are necessary when discussing physiological roles. 
What can a given number of molecules accomplish? 
# In the case of protein antigens, the authors should state if relevant genetically 
modified organisms exist. If they do, and are not used as controls, then the authors 
should explain why.  
 
Conclusions 
High quality data on protein localization and expression levels are important as the 
biomedical research community relies on them directly or indirectly. Publication of 
misleading data happens too often and has down-stream consequences. Rather than 
introducing more formal rules and regulations, it may be more effective to simply ask 
authors to explain why they believe their data are valid. The perfect negative control 
is usually unavailable and the pre-absorption test can give a false impression of 
specificity. It is important to combine immunocytochemistry both with other methods 
and with quantitative considerations, and then see if all the pieces of information add 
up. Finally, when doubt about validity arises in a late phase of a project, there may 
not be any good solutions at all. If money has run out and a PhD is at stake, non-
scientific factors will influence decisions. We hope that sharing our personal 
experiences will sensitize others to early warning signs and thereby facilitate 
navigation around some of the difficult situations we have found ourselves in, where 
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a lot of hard work and effort has turned out to have been wasted. 
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FIGURE LEGENDS 
Figure 1. Immunocytochemical labeling can always be obtained by adjusting assay 
conditions and cannot be used as proof of protein expression without a good 
negative control. Determination of optimal antibody concentrations is straightforward 
when tissues from knockout animals are available as negative controls. Sections 
from wild-type (WT) and EAAT3 (slc1a1)-deficient mice (KO) were incubated with 
either anti-C491 (Ab#371) or anti-C510 (Ab#565) antibodies to EAAT3 in 
concentrations as indicated. Note both that labeling is obtained in the EAAT3-
deficient tissue at high antibody concentrations, and that the anti-C491 antibody 
cross-reacts with a non-EAAT3 epitope even at low antibody concentrations in some 
regions (arrowheads: hippocampus and striatum). Scale bar = 2 mm. (Reproduced 
from Holmseth et al., 2012a, doi: 10.1369/0022155411434828). 
 
Figure 2. The C-terminus of EAAT2 is degraded faster than the central portion of the 
protein. Mouse brain tissue that stored for the indicated time after death (for methods 
see: Li et al., 2012), was subjected to Western blotting with the anti-B563 antibody 
(Ab#355; Holmseth et al., 2009) to the extreme C-terminus (residues 563-573) of rat 
EAAT2 and with the anti-B146 antibodies (Cat. No. 250 203; Synaptic Systems 
GmbH, Goettingen, Germany, www.sysy.com) central parts (residues 146-161). Each 
lane contained 30 µg total protein. Note that most of the immunoreactivity detected 
with Anti-B563 is gone after 24 hours post-mortem (at room temperature) while there 
is still substantial immunoreactivity after 72 hours with the anti-B146 antibodies. 
Tissue extracts from the EAAT2 knockout mice (GLT1-KO; Tanaka et al., 1997) were 
used as negative controls. 
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Figure 3. Confocal images of sections double labeled with anti-B563 antibodies 
(Ab#355; 0.1 µg/ml) to the C-terminus of EAAT2 and with anti-B493 antibodies to 
central parts of the protein (residues 493-508; Ab#8; 0.1 µg/ml; Li et al., 2012). Note 
that there is co-localization in freshly fixed tissue (0 h), but not in tissue stored at 
room temperature for 24 h before fixation. Tissue from EAAT2 knockout mice (GLT1-
KO; Tanaka et al., 1997) was used as negative controls. Scale bar: 20 µm. 
 
Figure 4. Oxidation of the EAAT2 makes higher molecular mass species appear on 
immunoblots (Trotti et al., 1998; Danbolt, 2001). These bands, however, are not seen 
if reducing agents (e.g. DTT, dithiothreitol) are added. Note that EAAT2 is mostly in 
monomer form if homogenized directly in SDS (Lane 1). On the other hand, if 
exposed to an SH-group oxidizer (DTNB, 5-(3-carboxy-4-nitrophenyl)disulfanyl-2-
nitrobenzoic acid) oligomer bands appear (Lane 2) unless excess DTT is added prior 
to electrophoresis (Lane 4). PMSF (phenylmethanesulfonyl fluoride) was added to 
inhibit proteases and NaPi (sodium phosphate) was chosen as buffer. The blot was 
developed with 0.2 µg/ml anti-B12 antibody (Ab#360 Holmseth et al., 2005). 
 
Figure 5. Protein aggregation with unknown relationship to the native oligomeric 
structure occurs at elevated temperatures when solubilized with mild detergents 
(Danbolt, 2001). Panel A: Brain membranes (the water insoluble pellet produced 
after homogenization in water followed by centrifugation) have been incubated with 
increasing concentrations of crosslinker as indicated, solubilized in SDS with 
dithiothreitol (DTT), mixed with SDS-sample buffer (2 % SDS) and subjected to 
electrophoresis (7 % acrylamide) followed by immunoblotting with anti-EAAT2 
antibodies (anti-B12 Ab#360; 0.2 µg/ml). Note that dimers and trimers are seen when 
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crosslinker is added. Panel B: Brain membranes were kept under reducing 
conditions (DTT added to all samples: Lanes 1-8). The membranes were solubilized 
in SDS (Lanes 1 and 2), cholate (Lanes 3-5) or Triton X-100 (Lanes 6-8). The 
extracts were either kept at room temperature (RT), at 0°C or at 37°C as indicated, 
and subjected to electrophoresis and immunoblotting as above. Note that monomers 
predominate in the SDS extracts. In the cholate and Triton extracts dimers and 
trimers are seen. The fraction of EAAT2 that runs as dimers or trimers increases if 
the extracts have been incubated at elevated temperatures. NB: Note that these 
dimers and trimers do not dissolve in the SDS sample buffer. Both panels: 
Proteases were inhibited with 5 mM EDTA (ethylenediaminetetraacetic acid) and 1 
mM PMSF (phenylmethylsulfonyl fluoride). 
 
Figure 6: Non-EAAT2 proteins interfere with EAAT2 immunodetection possibly by 
competition for binding sites on the nitrocellulose membrane. Panel A: application of 
increasing amounts 1.25, 2.5 and 5 µl of SDS solubilized transfected HEK293T cells 
leads to increased EAAT2 immunoreactivity on the blots. Panel B: SDS solubilized 
adult rat hippocampus (HC, 1 µg total tissue protein) was mixed with increasing 
amounts of SDS solubilized un-transfected HEK293T cells. Lanes 1-4 contain, 
respectively, (about 3, 9 or 30 µg total HEK293T cell protein. Note that the detection 
of hippocampal EAAT2 decreases with increasing amounts of cell extract. EAAT2 
was detected with anti-EAAT2a antibodies (Ab#355: 0.1 µg/ml) followed by HRP-
conjugated secondary antibodies. This figure is based on materials produced 
previously (Holmseth et al., 2009). 
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Figure 7. Antibodies to EAAT2 cross-react with a pancreatic water soluble protein 
(Zhou et al., 2014b). Pancreas from wildtype (WT) and EAAT2 knockout (KO) mice 
(Tanaka et al., 1997) were homogenized in water with protease inhibitors and 
centrifuged to separate the water soluble proteins (supernatant) from membrane 
proteins (pellet). Both the pellets and the supernatants were mixed with SDS-sample 
buffer and Western blotted with anti-B493 antibodies (Ab#95; 0.1 µg/ml) to EAAT2. 
The protein loading was first verified by Ponceau S staining (A), then destained and 
probed with the antibodies (B). Note that something with an electrophoretic mobility 
similar to EAAT2 was labeled, but that this was in the supernatants and from both 
WT and KO animals. There was no labeling of the membrane proteins. Spinal cord 
samples (C) were run for comparison. This was on the same electrophoresis gel and 
blot, but the blot was cut to hide lanes that were irrelevant in this context. Similar 
results were obtained with the anti-B12 antibody (Ab#360) to EAAT2 (not shown). 
Conclusion, EAAT2 could not be detected in pancreas.  
 
Figure 8. A high magnification transmission electron micrograph showing an 
asymmetric synapse in the cochlear nucleus of a guinea pig (section courtesy of Dr S 
Mahendrasingam, image by DNF). An axon terminal (T) with a mitochondrion (m) and 
multiple synaptic vesicles (sv) is synapsing onto a dendritic spine (S). The 
postsynaptic density (PSD) is the darker zone in the middle. The synaptic cleft is the 
narrow lighter line between the two arrowheads. Note the large amounts of plasma 
membranes. At least 10, possibly 11, different cellular compartments (cellular 
extensions) can be identified in the image. They are all separated by extracellular 
space bordered by the plasma membranes of neighboring cells. However, the 
membranes cannot be seen clearly in places where the membrane surface is oblique 
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relative to the image plane. The area indicated with the black box is shown at higher 
magnification (inset at the top right corner). The arrows point to the plasma 
membranes (dark lines). These are separate by a narrow zone which is the 
extracellular space. Note the thin astroglial extension in the lower right corner 
(asterisk). This extends upwards curving to the left (asterisk) in between three other 
cellular compartments. Scale bar 0.5 µm. 
 
Figure 9. Schematic illustration of the differences between pre-embedding 
peroxidase labeling (Upper panel) and post-embedding immunogold labeling (Lower 
panel). Two glutamatergic terminals are shown forming synapses onto spines (A and 
B) with asymmetric specializations post-synaptic specializations (Note prominent post 
synaptic densities, PSD, one of which is labeled). Nerve terminals are the structures 
with many synaptic vesicles (small open circles). GABAergic synapses (C) are often 
onto dendritic trunks rather than spines, and the synaptic specializations are typically 
symmetric. Three fine astrocyte branches are also indicated (g). The figure illustrates 
the typical labeling pattern obtained when using antibodies to intracellular epitopes 
on the EAAT2. EAAT2 is predominantly expressed in astrocytes (Danbolt et al., 
1992), but there is also some (about 10 %) in hippocampal nerve terminals (Furness 
et al., 2008; Danbolt et al., 2016). The upper panel shows labeling with 
immunoperoxidase (Lehre et al., 1995), while the lower panel shows immunogold 
labeling (Chaudhry et al., 1995). The peroxidase reaction product is electron dense, 
and therefore appears dark in the electron microscope. Note that it diffuses a little bit 
before it precipitates and thereby causes some labeling of the cytoplasm even when 
the proteins are predominantly at the surface. Also note that the labeling is 
intracellular. This pattern is seen when the antibodies bind to intracellular epitopes 
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and the plasma membranes are still intact (no freezing, no organic solvents and no 
detergents). This labeling is hard to quantify, but is excellent for identification of the 
labeled cell types. However, the images are monochromatic (gray scale) and it can 
be difficult to determine if a structure is naturally electron dense, dense due to 
contrasting (e.g. the PSDs and membranes) or dense because of antibody labeling. 
The latter problem is avoided by immunogold labeling (lower panel). But here the 
labeling is done after cutting of ultrathin sections. Note the scale bar at the bottom 
comparing the figure to a red blood cell. The gold particles (solid black dots) are 
attached to antibodies and can swing from side to side. Because the labeling is at a 
surface, the particles can swing freely and therefore can swing all the way over to the 
neighboring membrane (Amiry-Moghaddam and Ottersen, 2013). Thus, in this case it 
can be hard to be sure if only one of two neighboring membranes is labeled or if both 
are labeled. This high number of gold particles is only seen if the expression levels of 
the antigen are as high as those of EAAT2 (Lehre and Danbolt, 1998). (Copyright: 
Neurotransporter.org; Reproduced with permission). 
 
Figure 10. Panel A: Post-embedding immunogold labeling for EAAT2 on a 
hippocampal slice. Two terminals (T), an associated spine (Sp) and glial process (G) 
are visible. Gold-labeling is clearly predominant in the glial process, but there are 
ambiguous particles that could be localized either to the terminal membrane or the 
membrane of glial process (arrows).  Panel B: In a synaptosome preparation, 
isolated terminals (T) are separated from the associated glial membranes (G) and so 
unambiguous identification of terminal membrane labeling becomes possible 
(arrows). Scale bar = 200 nm. 
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Figure 11. An example of a convincing artifact that was discoveredbecause the 
labeling pattern was reproduced in the knockout mouse: Transmission electron 
microscopy of post-embedding immunogold labeling for EAAT3 (slc1a1) in the rat 
stratum radiatum (hippocampus CA1). The images show examples of varying 
synaptic morphology and patterns of immunogold labeling with an antibody (Ab#371) 
to EAAT3.  In all of these figures, spines are located to the left (sp in A) and 
presynaptic terminals to the right (pre in A). Unfortunately, these patterns were 
artifacts. We show the image here to illustrate the danger. We had worked hard to 
produce this figure, and when we had to scrap it, we had to scrap the entire paper. 
And that was a hard decision to make.  
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Figure 1. Immunocytochemical labeling can always be obtained by adjusting assay conditions and cannot be 
used as proof of protein expression without a good negative control. Determination of optimal antibody 
concentrations is straightforward when tissues from knockout animals are available as negative controls. 
Sections from wild-type (WT) and EAAT3 (slc1a1)-deficient mice (KO) were incubated with either anti-C491 
(Ab#371) or anti-C510 (Ab#565) antibodies to EAAT3 in concentrations as indicated. Note both that labeling 
is obtained in the EAAT3-deficient tissue at high antibody concentrations, and that the anti-C491 antibody 
cross-reacts with a non-EAAT3 epitope even at low antibody concentrations in some regions (arrowheads: 
hippocampus and striatum). Scale bar = 2 mm. (Reproduced from Holmseth et al., 2012a, doi: 
10.1369/0022155411434828).  
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Figure 2. The C-terminus of EAAT2 degrade faster than the central portion of the protein. Mouse brain tissue 
that stored for the indicated time after death (for methods see: Li et al., 2012), was subjected to Western 
blotting with the anti-B563 antibody (Ab#355; Holmseth et al., 2009) to the extreme C-terminus (residues 
563-573) of rat EAAT2 and with the anti-B146 antibodies (Cat. No. 250 203; Synaptic Systems GmbH, 
Goettingen, Germany, www.sysy.com) central parts (residues 146-161). Each lane contained 30 µg total 
protein. Note that most of the immunoreactivity detected with Anti-B563 is gone after 24 hours post-
mortem (at room temperature) while there is still substantial immunoreactivity after 72 hours with the anti-
B146 antibodies. Tissue extracts from the EAAT2 knockout mice (GLT1-KO; Tanaka et al., 1997) were used 
as negative controls.  
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Figure 3. Confocal images of sections double labeled with anti-B563 antibodies (Ab#355; 0.1 µg/ml) to the 
C-terminus of EAAT2 and with anti-B493 antibodies to central parts of the protein (residues 493-508; Ab#8; 
0.1 µg/ml; Li et al., 2012). Note that there is co-localization in freshly fixed tissue (0 h), but not in tissue 
stored at room temperature for 24 h before fixation. Tissue from EAAT2 knockout mice (GLT1-KO; Tanaka et 
al., 1997) was used as negative controls. Scale bar: 20 µm.  
106x67mm (300 x 300 DPI)  
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Figure 4. Oxidation of the EAAT2 makes higher molecular mass species appear on immunoblots (Trotti et al., 
1998; Danbolt, 2001). These bands, however, are not seen if reducing agents (e.g. DTT, dithiothreitol) are 
added. Note that EAAT2 is mostly in monomer form if homogenized directly in SDS (Lane 1). On the other 
hand, if exposed to an SH-group oxidizer (DTNB, 5-(3-carboxy-4-nitrophenyl)disulfanyl-2-nitrobenzoic acid) 
oligomer bands appear (Lane 2) unless excess DTT is added prior to electrophoresis (Lane 4). PMSF 
(phenylmethanesulfonyl fluoride) was added to inhibit proteases and NaPi (sodium phosphate) was chosen 
as buffer. The blot was developed with 0.2 µg/ml anti-B12 antibody (Ab#360 Holmseth et al., 2005).  
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Figure 5. Protein aggregation with unknown relationship to the native oligomeric structure occurs at elevated 
temperatures when solubilized with mild detergents (Danbolt, 2001). Panel A: Brain membranes (the water 
insoluble pellet produced after homogenization in water followed by centrifugation) have been incubated 
with increasing concentrations of crosslinker as indicated, solubilized in SDS with dithiothreitol (DTT), mixed 
with SDS-sample buffer (2 % SDS) and subjected to electrophoresis (7 % acrylamide) followed by 
immunoblotting with anti-EAAT2 antibodies (anti-B12 Ab#360; 0.2 µg/ml). Note that dimers and trimers are 
seen when crosslinker is added. Panel B: Brain membranes were kept under reducing conditions (DTT added 
to all samples: Lanes 1-8). The membranes were solubilized in SDS (Lanes 1 and 2), cholate (Lanes 3-5) or 
Triton X-100 (Lanes 6-8). The extracts were either kept at room temperature (RT), at 0°C or at 37°C as 
indicated, and subjected to electrophoresis and immunoblotting as above. Note that monomers predominate 
in the SDS extracts. In the cholate and Triton extracts dimers and trimers are seen. The fraction of EAAT2 
that runs as dimers or trimers increases if the extracts have been incubated at elevated temperatures. NB: 
Note that these dimers and trimers do not dissolve in the SDS sample buffer. Both panels: Proteases were 
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inhibited with 5 mM EDTA (ethylenediaminetetraacetic acid) and 1 mM PMSF (phenylmethylsulfonyl 
fluoride).  
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Figure 6: Non-EAAT2 proteins interfere with EAAT2 immunodetection possibly by competition for binding 
sites on the nitrocellulose membrane. Panel A: application of increasing amounts 1.25, 2.5 and 5 µl of SDS 
solubilized transfected HEK293T cells leads to increased EAAT2 immunoreactivity on the blots. Panel B: SDS 
solubilized adult rat hippocampus (HC, 1 µg total tissue protein) was mixed with increasing amounts of SDS 
solubilized un-transfected HEK293T cells. Lanes 1-4 contain, respectively, (about 3, 9 or 30 µg total 
HEK293T cell protein. Note that the detection of hippocampal EAAT2 decreases with increasing amounts of 
cell extract. EAAT2 was detected with anti-EAAT2a antibodies (Ab#355: 0.1 µg/ml) followed by HRP-
conjugated secondary antibodies. This figure is based on materials produced previously (Holmseth et al., 
2009).  
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Figure 7. Antibodies to EAAT2 cross-react with a pancreatic water soluble protein (Zhou et al., 2014b). 
Pancreas from wildtype (WT) and EAAT2 knockout (KO) mice (Tanaka et al., 1997) were homogenized in 
water with protease inhibitors and centrifuged to separate the water soluble proteins (supernatant) from 
membrane proteins (pellet). Both the pellets and the supernatants were mixed with SDS-sample buffer and 
Western blotted with anti-B493 antibodies (Ab#95; 0.1 µg/ml) to EAAT2. The protein loading was first 
verified by Ponceau S staining (A), then destained and probed with the antibodies (B). Note that something 
with an electrophoretic mobility similar to EAAT2 was labeled, but that this was in the supernatants and 
from both WT and KO animals. There was no labeling of the membrane proteins. Spinal cord samples (C) 
were run for comparison. This was on the same electrophoresis gel and blot, but the blot was cut to hide 
lanes that were irrelevant in this context. Similar results were obtained with the anti-B12 antibody (Ab#360) 
to EAAT2 (not shown). Conclusion, EAAT2 could not be detected in pancreas.  
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Figure 8. A high magnification transmission electron micrograph showing an asymmetric synapse in the 
cochlear nucleus of a guinea pig (section courtesy of Dr S Mahendrasingam, image by DNF). An axon 
terminal (T) with a mitochondrion (m) and multiple synaptic vesicles (sv) is synapsing onto a dendritic spine 
(S). The postsynaptic density (PSD) is the darker zone in the middle. The synaptic cleft is the narrow lighter 
line between the two arrowheads. Note the large amounts of plasma membranes. At least 10, possibly 11, 
different cellular compartments (cellular extensions) can be identified in the image. They are all separated 
by extracellular space bordered by the plasma membranes of neighboring cells. However, the membranes 
cannot be seen clearly in places where the membrane surface is oblique relative to the image plane. The 
area indicated with the black box is shown at higher magnification (inset at the top right corner). The arrows 
point to the plasma membranes (dark lines). These are separate by a narrow zone which is the extracellular 
space. Note the thin astroglial extension in the lower right corner (asterisk). This extends upwards curving 
to the left (asterisk) in between three other cellular compartments. Scale bar 0.5 µm.  
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Figure 9. Schematic illustration of the differences between pre-embedding peroxidase labeling (Upper panel) 
and post-embedding immunogold labeling (Lower panel). Two glutamatergic terminals are shown forming 
synapses onto spines (A and B) with asymmetric specializations post-synaptic specializations (Note 
prominent post synaptic densities, PSD, one of which is labeled). Nerve terminals are the structures with 
many synaptic vesicles (small open circles). GABAergic synapses (C) are often onto dendritic trunks rather 
than spines, and the synaptic specializations are typically symmetric. Three fine astrocyte branches are also 
indicated (g). The figure illustrates the typical labeling pattern obtained when using antibodies to 
intracellular epitopes on the EAAT2. EAAT2 is predominantly expressed in astrocytes (Danbolt et al., 1992), 
but there is also some (about 10 %) in hippocampal nerve terminals (Furness et al., 2008; Danbolt et al., 
2016). The upper panel shows labeling with immunoperoxidase (Lehre et al., 1995), while the lower panel 
shows immunogold labeling (Chaudhry et al., 1995). The peroxidase reaction product is electron dense, and 
therefore appears dark in the electron microscope. Note that it diffuses a little bit before it precipitates and 
thereby causes some labeling of the cytoplasm even when the proteins are predominantly at the surface. 
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Also note that the labeling is intracellular. This pattern is seen when the antibodies bind to intracellular 
epitopes and the plasma membranes are still intact (no freezing, no organic solvents and no detergents). 
This labeling is hard to quantify, but is excellent for identification of the labeled cell types. However, the 
images are monochromatic (gray scale) and it can be difficult to determine if a structure is naturally electron 
dense, dense due to contrasting (e.g. the PSDs and membranes) or dense because of antibody labeling. The 
latter problem is avoided by immunogold labeling (lower panel). But here the labeling is done after cutting 
of ultrathin sections. Note the scale bar at the bottom comparing the figure to a red blood cell. The gold 
particles (solid black dots) are attached to antibodies and can swing from side to side. Because the labeling 
is at a surface, the particles can swing freely and therefore can swing all the way over to the neighboring 
membrane (Amiry-Moghaddam and Ottersen, 2013). Thus, in this case it can be hard to be sure if only one 
of two neighboring membranes is labeled or if both are labeled. This high number of gold particles is only 
seen if the expression levels of the antigen are as high as those of EAAT2 (Lehre and Danbolt, 1998). 
(Copyright: Neurotransporter.org; Reproduced with permission).  
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Figure 10. Panel A: Post-embedding immunogold labeling for EAAT2 on a hippocampal slice. Two terminals 
(T), an associated spine (Sp) and glial process (G) are visible. Gold-labeling is clearly predominant in the 
glial process, but there are ambiguous particles that could be localized either to the terminal membrane or 
the membrane of glial process (arrows).  Panel B: In a synaptosome preparation, isolated terminals (T) are 
separated from the associated glial membranes (G) and so unambiguous identification of terminal 
membrane labeling becomes possible (arrows). Scale bar = 200 nm.  
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Figure 11. An example of a convincing artifact that was discoveredbecause the labeling pattern was 
reproduced in the knockout mouse: Transmission electron microscopy of post-embedding immunogold 
labeling for EAAT3 (slc1a1) in the rat stratum radiatum (hippocampus CA1). The images show examples of 
varying synaptic morphology and patterns of immunogold labeling with an antibody (Ab#371) to EAAT3.  In 
all of these figures, spines are located to the left (sp in A) and presynaptic terminals to the right (pre in A). 
Unfortunately, these patterns were artifacts. We show the image here to illustrate the danger. We had 
worked hard to produce this figure, and when we had to scrap it, we had to scrap the entire paper. And that 
was a hard decision to make.  
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Table 1 
Source Web 
Allan Brain Atlas http://connectivity.brain-
map.org/transgenic/search/basic 
International Knockout Mouse Consortium www.knockoutmouse.org 
Mouse Genome Informatics www.informatics.jax.org 
NIH Mouse Initiatives - The Knockout 
Mouse Project 
http://www.genome.gov/17515708 
Gene Expression Nervous System Atlas 
(GENSAT) 
http://www.gensat.org/daily_showcase.jsp 
Cre-lines and Bac-mice http://www.gensat.org/cre.jsp 
http://cre.jax.org/data.html  
International Mouse Phenotyping 
Consortium 
http://www.mousephenotype.org/data/search 
Mutant Mouse Regional Resource Centers 
(MMRRC 
https://www.mmrrc.org/index.php 
A large number of modified animals are available. Before starting a knockout or 
conditional knockout project, it is a good idea to check if the gene of interest has 
been targeted and the availability of the targeting vector/ES cell clones/mice.  
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